NVL-520 is a medication being studied for its potential to treat patients with advanced solid tumors that are positive for ROS1, a specific type of genetic alteration. This medication is a highly selective inhibitor, meaning it specifically targets and blocks the activity of the ROS1 protein, which may help to slow down or stop the growth of cancer cells. The trial aims to find the most effective dose of NVL-520 and to assess how well it works in treating patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.

Advanced ROS1-positive Non-Small Cell Lung Cancer (NSCLC) – This is a type of lung cancer characterized by the presence of a specific genetic alteration known as ROS1 rearrangement. It typically occurs in younger patients who are non-smokers or light smokers. The disease progresses as cancer cells grow and spread in the lungs and potentially to other parts of the body. Symptoms may include persistent cough, chest pain, and shortness of breath. As the disease advances, it can lead to more severe respiratory issues and general health decline. The presence of ROS1-positive tumors can influence the choice of targeted therapies.

Advanced ROS1-positive Solid Tumors – These are a group of cancers that occur in various organs and tissues, characterized by the presence of ROS1 gene rearrangements. Such tumors can develop in different parts of the body, including the lungs, brain, and gastrointestinal tract. The disease progresses as the cancer cells multiply and invade surrounding tissues, potentially spreading to distant organs. Symptoms vary depending on the tumor’s location but may include pain, swelling, or dysfunction of the affected organ. The ROS1-positive status of these tumors can guide specific treatment approaches. As the disease advances, it can lead to significant health challenges and complications.